Skip to content

Monitoring and comparing the improvement of hair growth using minoxidil(5%) versus Minoxidil(5%) and Finasteride (0.1%) combination in subjects male pattern baldness

Study of the safety and efficacy of topical minoxidil(5%) versus Minoxidil(5%) and Finasteride (0.1%) combination in the treatment of androgenetic alopecia in men

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/05/014262
Enrollment
40
Registered
2018-05-31
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Androgenetic alopecia in men

Interventions

Intervention1: Minoxidil 5%: Minoxidil 5% should be applied 1ml twice daily over the scalp for 4 months Control Intervention1: Morrf: Minoxidil(5%) + Finasteride (0.1%) should be applied 1 ml twice d

Sponsors

Dr Alex James
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Male patients between 18-45 years. 2.Patients with grade II â??IV of modified Norwood Hamilton classification of AGA. 3.Men willing to use the same shampoo and maintain same hair length and colour for the entire duration of the study.

Exclusion criteria

Exclusion criteria: 1.Patients who are not willing for the study. 2.Patients with dermatological disorders on the scalp other than AGA. 3.Patients with serious cardiovascular, renal or hepatic disease. 4.Patients with history of drug hypersensitivity. 5.Patients who are using any other therapy for AGA.

Design outcomes

Primary

MeasureTime frame
Increase in hair growthTimepoint: Increase in hair growth after and growth will be assessed at initial visit, 8th week and 16th week

Secondary

MeasureTime frame
itching, erythema and dandruff.Timepoint: To be assessed at initial visit, 8th week and 16th week

Countries

India

Contacts

Public ContactDr Alex James

Father muller medical college

dr_martisj@yahoo.co.in9845148112

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026